Phase I Trial of Carfilzomib + R-CHOP (CarR-CHOP) for Frontline Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
CONCLUSION: CarR-CHOP is safe at a recommended phase II dose of 20 mg/m2 on day 1 & 2 for cycle 1 followed by 56 mg/m2 for cycles 2-6, without significant excess cardiac effects. Within the limitations of a prospective phase I clinical trial with potential patient selection bias, preliminary efficacy data suggest a high complete metabolic response rate and equivalent outcomes for patients with GC and non-GC subtype. Phase II accrual is ongoing for non-GC DLBCL only and additional correlative studies of the molecular subtype of DLBCL will be incorporated into future analysis.DisclosuresHill: Amgen: Research Funding; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pharmacyclics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Genentech: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership...
Source: Blood - Category: Hematology Authors: Hill, B. T., Dean, R. M., Jagadeesh, D., Mejia Garcia, A. V., Pohlman, B., Winter, A. M., Krauspe, E., Collier, P., D'Andrea, C., Morrison, A., Lehmann, S., Tomlinson, B. K., Cooper, B., de Lima, M., Ondrejka, S. L., Hsi, E. D., Caimi, P. Tags: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Prospective Clinical Trials: Poster I Source Type: research
More News: Acyclovir | Anemia | Brain | Cancer | Cancer & Oncology | Clinical Trials | Genetics | Headache | Hematology | Hodgkin's Disease | Hypertension | Lung Cancer | Lymphoma | Migraine | Molecular Biology | Neurology | Pfizer | Pharmaceuticals | Rituxan | Statistics | Study | Thrombocytopenia | Toxicology | Velcade | Zovirax